U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07543757) titled 'Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix' on April 14.
Brief Summary: The study is a prospective, multi-center, single cohort study involving up to 10 urological clinics in the US. After provision of informed consent and prior to the scheduled prostate biopsy (≤30 days), up to 20 mL of whole blood will be collected from each subject. The samples will be blinded and sent to Labcorp for evaluation using the Proclarix(R) assay. Prostate biopsy will be performed according to standard clinical practice of the urologist (systematic, targeted, or ...